Luis Morales Ojeda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luis Morales Ojeda has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Stefania Montero
Department of Urology
6 shared publications Donald L. Jacobs
4 shared publicationsKay Jann
USC Stevens Neuroimaging and Informatics Institute University of Southern California Los Angeles California USA
4 shared publicationsPriya Kohli
Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California
4 shared publications- Rafael Demarchi Malgor
Division of Vascular and Endovascular Surgery, University of Colorado, Anschutz Medical Center, Aurora, CO
4 shared publications Stefania Montero
Rancho Research Institute, Rancho Los Amigos National Rehabilitation Center, Downey, California
4 shared publications
Latest Publications
- Open Access
- 16 November 2026
- Published by Elsevier in EJVES Vascular Forum
Comparative Outcomes of Thoracoabdominal Aortic Aneurysms Treated with Physician Modified Endografts in Elective, Urgent, and Emergency Settings
- 16 November 2026
- Published by Elsevier in EJVES Vascular Forum
Open AccessComparative Outcomes of Thoracoabdominal Aortic Aneurysms Treated with Physician Modified Endografts in Elective, Urgent, and Emergency Settings
- Open Access
- 10 November 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- p. e055325
Comparative Efficacy and Safety of Four Novel Monoclonal Antibody PCSK9 Inhibitors: A Bayesian Network Meta‐Analysis of Lipid and Safety Outcomes
Background: Four novel monoclonal antibody proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors—tafolecimab, ongericimab, ebronucimab, and recaticimab—lower low‐density lipoprotein cholesterol (LDL‐C) in placebo‐controlled trials but have never been compared head to head. Methods: We searched PubMed, Embase, Scopus, CENTRAL, and ClinicalTrials.gov from inception to 8 June 2026 and performed a Bayesian random‐effects network meta‐analysis of randomized placebo‐controlled trials across eight lipid outcomes, analyzed by dose–interval regimen, and adverse events, analyzed by drug (PROSPERO CRD420261422519). Risk of bias was assessed with RoB 2 and certainty of evidence with CINeMA. Lipid effects are placebo‐adjusted differences in percentage change from baseline with 95% credible intervals (CrIs). Results: Thirteen trials were included. In the LDL‐C network (4,517 patients; 16 regimens), every regimen lowered LDL‐C (−45.2% to −80.2%), with concordant reductions in non–high‐density lipoprotein cholesterol, apolipoprotein B, and total cholesterol. Most between‐agent differences were small, but some indirect contrasts had CrIs excluding zero; most consistently, ongericimab 150 mg every 2 weeks lowered LDL‐C more than the three phase 3 recaticimab regimens (differences −14.4% to −18.6%), robust to adjustment for background statin therapy and baseline LDL‐C. Rank intervals were wide. The largest triglyceride and high‐density lipoprotein cholesterol effects of recaticimab were confined to small phase 1b/2 regimens. No agent differed from placebo for any adverse event or serious adverse events, although information was limited; injection‐site reactions were more frequent with active treatment. Certainty of evidence was moderate to very low versus placebo and very low between agents. Conclusions: All four antibodies produced substantial reductions in atherogenic lipids without a detected safety signal beyond injection‐site reactions. Indirect between‐agent differences are hypothesis‐generating and do not establish a hierarchy; head‐to‐head and cardiovascular outcome trials are needed.
- 10 November 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- p. e055325
Open AccessComparative Efficacy and Safety of Four Novel Monoclonal Antibody PCSK9 Inhibitors: A Bayesian Network Meta‐Analysis of Lipid and Safety Outcomes
Background: Four novel monoclonal antibody proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors—tafolecimab, ongericimab, ebronucimab, and recaticimab—lower low‐density lipoprotein cholesterol (LDL‐C) in placebo‐controlled trials but have never been compared head to head. Methods: We searched PubMed, Embase, Scopus, CENTRAL, and ClinicalTrials.gov from inception to 8 June 2026 and performed a Bayesian random‐effects network meta‐analysis of randomized placebo‐controlled trials across eight lipid outcomes, analyzed by dose–interval regimen, and adverse events, analyzed by drug (PROSPERO CRD420261422519). Risk of bias was assessed with RoB 2 and certainty of evidence with CINeMA. Lipid effects are placebo‐adjusted differences in percentage change from baseline with 95% credible intervals (CrIs). Results: Thirteen trials were included. In the LDL‐C network (4,517 patients; 16 regimens), every regimen lowered LDL‐C (−45.2% to −80.2%), with concordant reductions in non–high‐density lipoprotein cholesterol, apolipoprotein B, and total cholesterol. Most between‐agent differences were small, but some indirect contrasts had CrIs excluding zero; most consistently, ongericimab 150 mg every 2 weeks lowered LDL‐C more than the three phase 3 recaticimab regimens (differences −14.4% to −18.6%), robust to adjustment for background statin therapy and baseline LDL‐C. Rank intervals were wide. The largest triglyceride and high‐density lipoprotein cholesterol effects of recaticimab were confined to small phase 1b/2 regimens. No agent differed from placebo for any adverse event or serious adverse events, although information was limited; injection‐site reactions were more frequent with active treatment. Certainty of evidence was moderate to very low versus placebo and very low between agents. Conclusions: All four antibodies produced substantial reductions in atherogenic lipids without a detected safety signal beyond injection‐site reactions. Indirect between‐agent differences are hypothesis‐generating and do not establish a hierarchy; head‐to‐head and cardiovascular outcome trials are needed.
- Open Access
- 28 September 2026
- Published by Elsevier in SSRN Electronic Journal
Pyruvate Dehydrogenase Kinase Inhibition Increases Mitochondrial Respiratory Capacity in Senescent Hepatic Cells under Burn-Like Stress
Severe burn injury is a systemic metabolic emergency in which the liver must rapidly adjust mitochondrial substrate oxidation. Aging worsens burn outcomes, and aged tissues accumulate senescent cells, yet whether senescence impairs the hepatic respiratory response to injury is unknown. Here, we show that burn injury induces a hepatic stress program with elevated pyruvate dehydrogenase kinase 4 (PDK4), most pronounced in the livers of aged mice. Bleomycin-induced senescent AML12 cells recapitulate this PDK4-high state. Non-senescent AML12 cells respond to a burn-mimetic medium with increased basal and maximal respiration, whereas no corresponding increase in maximal respiration is detected in senescent cells. Under burn-like stress, PDK4-IN-1 and AZD7545 increase maximal respiratory capacity and CCK-8 signal in senescent cells; AZD7545 also increases spare respiratory capacity. PDK inhibitor treatment reduces PDH Ser293 phosphorylation. These findings identify the PDK-PDH axis as a candidate modulator of hepatic cellular stress responses and support further preclinical investigation, without establishing isoform-specific causality or therapeutic efficacy in burned animals.
- 28 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPyruvate Dehydrogenase Kinase Inhibition Increases Mitochondrial Respiratory Capacity in Senescent Hepatic Cells under Burn-Like Stress
Severe burn injury is a systemic metabolic emergency in which the liver must rapidly adjust mitochondrial substrate oxidation. Aging worsens burn outcomes, and aged tissues accumulate senescent cells, yet whether senescence impairs the hepatic respiratory response to injury is unknown. Here, we show that burn injury induces a hepatic stress program with elevated pyruvate dehydrogenase kinase 4 (PDK4), most pronounced in the livers of aged mice. Bleomycin-induced senescent AML12 cells recapitulate this PDK4-high state. Non-senescent AML12 cells respond to a burn-mimetic medium with increased basal and maximal respiration, whereas no corresponding increase in maximal respiration is detected in senescent cells. Under burn-like stress, PDK4-IN-1 and AZD7545 increase maximal respiratory capacity and CCK-8 signal in senescent cells; AZD7545 also increases spare respiratory capacity. PDK inhibitor treatment reduces PDH Ser293 phosphorylation. These findings identify the PDK-PDH axis as a candidate modulator of hepatic cellular stress responses and support further preclinical investigation, without establishing isoform-specific causality or therapeutic efficacy in burned animals.
- 9 February 2026
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 71 (2) , e35-e36
The value of vascular surgeons in modern health care systems: A systematic review and meta-analysis
- 9 February 2026
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 71 (2) , e35-e36
The value of vascular surgeons in modern health care systems: A systematic review and meta-analysis
- 30 October 2025
- Published by SAGE Publications in Vascular
- Vol. 34 (3) , 587-597
The role of doxycycline in reducing MMP-9 and acute-phase reactants to limit abdominal aortic aneurysm growth: A systematic review
Background: Abdominal aortic aneurysms (AAAs) are a significant vascular disease characterized by the degradation of medial elastic lamellae, neovascularization, and inflammatory responses. While surgical intervention remains the standard treatment for large or rapidly expanding AAAs, there is no universally accepted pharmacological therapy to prevent aneurysm progression. Matrix metalloproteinases (MMPs), particularly MMP-9, and inflammatory markers such as high-sensitivity C-reactive protein (hs-CRP) are implicated in AAA pathogenesis, making them potential therapeutic targets. Doxycycline, a broad-spectrum tetracycline antibiotic, has demonstrated inhibitory effects on MMP-9 and anti-inflammatory properties. However, its efficacy in slowing AAA progression remains unclear. Methods: A systematic review was conducted following PRISMA guidelines. Electronic searches were performed in PubMed, MEDLINE, EMBASE, and ClinicalTrials.gov. Inclusion criteria encompassed randomized controlled trials (RCTs), cohort studies, in vitro studies, and systematic reviews evaluating the effects of doxycycline on AAA growth. Data extraction was performed using Covidence software, and study quality was assessed using the Cochrane Risk of Bias Tool 2.0 (RoB2) for RCTs, the QUIN tool for in vitro studies, and the SYRCLE tool for animal experiments. Statistical analysis employed a random-effects model to evaluate heterogeneity among studies. Results: The initial search identified 1313 references, of which 10 studies met inclusion criteria: two RCTs, two systematic reviews, three in vitro studies, one in vivo study, one methodological study, and one experimental study. The two RCTs, involving 515 patients with an average age of 71 years, reported minimal to no significant reductions in AAA growth following doxycycline administration. In contrast, in vitro and in vivo studies demonstrated inhibition of MMP-9 and inflammatory markers, supporting doxycycline’s potential therapeutic role. Meta-analysis was not performed due to high heterogeneity (I 2 = 75%). Risk of bias assessment indicated a low risk for RCTs, whereas in vitro and in vivo studies showed a moderate risk of bias. Conclusion: While doxycycline exhibits promising biochemical effects in AAA pathophysiology, its clinical efficacy remains uncertain. Current evidence does not support its routine use in AAA management outside clinical trials. Future research should focus on targeted pharmacotherapy integrating patient-specific biomarkers to enhance therapeutic outcomes.
- 30 October 2025
- Published by SAGE Publications in Vascular
- Vol. 34 (3) , 587-597
The role of doxycycline in reducing MMP-9 and acute-phase reactants to limit abdominal aortic aneurysm growth: A systematic review
Background: Abdominal aortic aneurysms (AAAs) are a significant vascular disease characterized by the degradation of medial elastic lamellae, neovascularization, and inflammatory responses. While surgical intervention remains the standard treatment for large or rapidly expanding AAAs, there is no universally accepted pharmacological therapy to prevent aneurysm progression. Matrix metalloproteinases (MMPs), particularly MMP-9, and inflammatory markers such as high-sensitivity C-reactive protein (hs-CRP) are implicated in AAA pathogenesis, making them potential therapeutic targets. Doxycycline, a broad-spectrum tetracycline antibiotic, has demonstrated inhibitory effects on MMP-9 and anti-inflammatory properties. However, its efficacy in slowing AAA progression remains unclear. Methods: A systematic review was conducted following PRISMA guidelines. Electronic searches were performed in PubMed, MEDLINE, EMBASE, and ClinicalTrials.gov. Inclusion criteria encompassed randomized controlled trials (RCTs), cohort studies, in vitro studies, and systematic reviews evaluating the effects of doxycycline on AAA growth. Data extraction was performed using Covidence software, and study quality was assessed using the Cochrane Risk of Bias Tool 2.0 (RoB2) for RCTs, the QUIN tool for in vitro studies, and the SYRCLE tool for animal experiments. Statistical analysis employed a random-effects model to evaluate heterogeneity among studies. Results: The initial search identified 1313 references, of which 10 studies met inclusion criteria: two RCTs, two systematic reviews, three in vitro studies, one in vivo study, one methodological study, and one experimental study. The two RCTs, involving 515 patients with an average age of 71 years, reported minimal to no significant reductions in AAA growth following doxycycline administration. In contrast, in vitro and in vivo studies demonstrated inhibition of MMP-9 and inflammatory markers, supporting doxycycline’s potential therapeutic role. Meta-analysis was not performed due to high heterogeneity (I 2 = 75%). Risk of bias assessment indicated a low risk for RCTs, whereas in vitro and in vivo studies showed a moderate risk of bias. Conclusion: While doxycycline exhibits promising biochemical effects in AAA pathophysiology, its clinical efficacy remains uncertain. Current evidence does not support its routine use in AAA management outside clinical trials. Future research should focus on targeted pharmacotherapy integrating patient-specific biomarkers to enhance therapeutic outcomes.
- 29 October 2025
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 83 (3) , 933-951
The value of vascular surgeons in modern health care systems: A systematic review and meta-analysis
- 29 October 2025
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 83 (3) , 933-951
The value of vascular surgeons in modern health care systems: A systematic review and meta-analysis
- 1 May 2025
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 213 (5) , 617-627
Long-Term Decision Regret and Associated Factors After Urinary Reconstruction in Underserved Patients With Spinal Cord Injury
Patients with refractory neurogenic bladder dysfunction may require urinary reconstruction due to severe incontinence, difficulty with catheterization, and to prevent upper urinary tract compromise. We evaluated long-term decisional regret and associated factors after urinary reconstruction in patients with spinal cord injury. We interviewed patients with spinal cord injuries who underwent bladder reconstruction surgery at least 10 years ago, administering validated surveys on bowel quality of life (QoL) and dysfunction, UTIs, and decisional regret. Daily bladder management and symptoms were assessed using the Neurogenic Bladder Symptom Score, a validated questionnaire consisting of 3 domains that examine incontinence, storage and voiding, and other health and QoL consequences of neurogenic lower urinary tract dysfunction. Demographics, injury characteristics, and surgical modality were collected through chart reviews. Decisional regret was compared among subgroups and correlated with patient-reported outcomes. We evaluated 52 patients (41 men, 78.8%; mean age 54.9 ± 10 years) with average follow-up of 30 ± 8.6 years of postinjury and 21.9 ± 5.3 years of postsurgery. Reconstruction procedures mostly included bladder augmentation (n = 38, 73.1%) and augmentation with continent catheterizable stoma (n = 9, 17.3%). Most of the patients were of Hispanic origin (n = 41, 78.8%) with complete spinal cord injuries (n = 39, 76%). The median decision regret score was 7.5 (IQR: 0-25), indicating low regret among most participants. Bladder irrigation frequency (P = .002) was associated with decision regret, while other patient and surgical factors (eg, demographics, UTI frequency, and surgery type) were not. Surgical regret was moderately correlated with diminished bowel-related QoL (ρ = 0.333, P = .016) and increased Neurogenic Bladder Symptom Score (ρ = 0.328, P = .018). The Incontinence (ρ = 0.286, P = .040) and Consequences (ρ = 0.299, P = .031) domains of this measure showed weak statistically significant correlations with regret, while the Storage and Voiding domain did not reach significance (ρ = 0.245, P = .080). Long-term follow-up suggests that lower urinary tract reconstruction with bowel interposition is a well-accepted and durable approach for managing refractory neurogenic bladder. Factors associated with decision regret, such as need for irrigation, should be incorporated in patient-centered decision-making.
- 1 May 2025
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 213 (5) , 617-627
Long-Term Decision Regret and Associated Factors After Urinary Reconstruction in Underserved Patients With Spinal Cord Injury
Patients with refractory neurogenic bladder dysfunction may require urinary reconstruction due to severe incontinence, difficulty with catheterization, and to prevent upper urinary tract compromise. We evaluated long-term decisional regret and associated factors after urinary reconstruction in patients with spinal cord injury. We interviewed patients with spinal cord injuries who underwent bladder reconstruction surgery at least 10 years ago, administering validated surveys on bowel quality of life (QoL) and dysfunction, UTIs, and decisional regret. Daily bladder management and symptoms were assessed using the Neurogenic Bladder Symptom Score, a validated questionnaire consisting of 3 domains that examine incontinence, storage and voiding, and other health and QoL consequences of neurogenic lower urinary tract dysfunction. Demographics, injury characteristics, and surgical modality were collected through chart reviews. Decisional regret was compared among subgroups and correlated with patient-reported outcomes. We evaluated 52 patients (41 men, 78.8%; mean age 54.9 ± 10 years) with average follow-up of 30 ± 8.6 years of postinjury and 21.9 ± 5.3 years of postsurgery. Reconstruction procedures mostly included bladder augmentation (n = 38, 73.1%) and augmentation with continent catheterizable stoma (n = 9, 17.3%). Most of the patients were of Hispanic origin (n = 41, 78.8%) with complete spinal cord injuries (n = 39, 76%). The median decision regret score was 7.5 (IQR: 0-25), indicating low regret among most participants. Bladder irrigation frequency (P = .002) was associated with decision regret, while other patient and surgical factors (eg, demographics, UTI frequency, and surgery type) were not. Surgical regret was moderately correlated with diminished bowel-related QoL (ρ = 0.333, P = .016) and increased Neurogenic Bladder Symptom Score (ρ = 0.328, P = .018). The Incontinence (ρ = 0.286, P = .040) and Consequences (ρ = 0.299, P = .031) domains of this measure showed weak statistically significant correlations with regret, while the Storage and Voiding domain did not reach significance (ρ = 0.245, P = .080). Long-term follow-up suggests that lower urinary tract reconstruction with bowel interposition is a well-accepted and durable approach for managing refractory neurogenic bladder. Factors associated with decision regret, such as need for irrigation, should be incorporated in patient-centered decision-making.
- 29 December 2024
- Published by Wiley in Neurourology and Urodynamics
- Vol. 44 (2) , 374-381
Using Functional Magnetic Resonance Imaging to Detect Differences in Micturition‐Related Brain Activity Between Volitional and Involuntary Detrusor Contractions
Introduction: Detrusor contractions can be classified as either volitional or involuntary. The latter are a hallmark of urge urinary incontinence. Understanding differences in neuroactivation associated with both types of contractions can help elucidate pathophysiology and therapeutic targets. In this study we aim to compare brain activity associated with voluntary and involuntary detrusor contractions.Methods: Twenty seven stroke survivors with secondary storage lower urinary tract symptoms underwent four filling cycles of simultaneous urodynamics and BOLD‐signal fMRI. After each fill, participants were instructed to void. Voids inside the designated 10‐s period were considered voluntary contractions. All others were considered involuntary. Each contraction was then segmented into phases: Early (10 s before start of contraction), Rise (start of contraction to peak vesical pressure), Plateau, and Fall (from peak pressure to resolution of the contraction). BOLD‐effect was compared between the two contraction types, employing a minimum cluster size of 25 voxels and significance threshold at p < 0.005.Results: Compared to volitional contractions, involuntary contractions were associated with diminished brain activity in each contraction phase. During the Early phase, this difference was most prominent in areas implicated with sensory and autonomic function, shifting to regions tasked with motor control as the contraction continued and eventually attenuating as the contraction resolved.Conclusion: This study uniquely contrasts brain activation associated with volitional and involuntary contractions. Relative to involuntary contractions, volitional contractions revealed increased activity in motor, sensory, and executive functioning regions. These findings reflect both the physiological mechanism of volitional contractions and suggest the displacement of this mechanism by a subcortical reflex in involuntary contractions.Clinical Trial Registration: NCT05301335.
- 29 December 2024
- Published by Wiley in Neurourology and Urodynamics
- Vol. 44 (2) , 374-381
Using Functional Magnetic Resonance Imaging to Detect Differences in Micturition‐Related Brain Activity Between Volitional and Involuntary Detrusor Contractions
Introduction: Detrusor contractions can be classified as either volitional or involuntary. The latter are a hallmark of urge urinary incontinence. Understanding differences in neuroactivation associated with both types of contractions can help elucidate pathophysiology and therapeutic targets. In this study we aim to compare brain activity associated with voluntary and involuntary detrusor contractions.Methods: Twenty seven stroke survivors with secondary storage lower urinary tract symptoms underwent four filling cycles of simultaneous urodynamics and BOLD‐signal fMRI. After each fill, participants were instructed to void. Voids inside the designated 10‐s period were considered voluntary contractions. All others were considered involuntary. Each contraction was then segmented into phases: Early (10 s before start of contraction), Rise (start of contraction to peak vesical pressure), Plateau, and Fall (from peak pressure to resolution of the contraction). BOLD‐effect was compared between the two contraction types, employing a minimum cluster size of 25 voxels and significance threshold at p < 0.005.Results: Compared to volitional contractions, involuntary contractions were associated with diminished brain activity in each contraction phase. During the Early phase, this difference was most prominent in areas implicated with sensory and autonomic function, shifting to regions tasked with motor control as the contraction continued and eventually attenuating as the contraction resolved.Conclusion: This study uniquely contrasts brain activation associated with volitional and involuntary contractions. Relative to involuntary contractions, volitional contractions revealed increased activity in motor, sensory, and executive functioning regions. These findings reflect both the physiological mechanism of volitional contractions and suggest the displacement of this mechanism by a subcortical reflex in involuntary contractions.Clinical Trial Registration: NCT05301335.
- Open Access
- 29 November 2024
- Published by Springer Nature in Cureus
- Vol. 16 (11) , e74740
The Effect of Fluoroquinolones on Aortic Aneurysm and Dissection
Fluoroquinolones (FQs) are a widely prescribed class of antibiotics including ciprofloxacin, levofloxacin, and ofloxacin. They are commonly used to treat a variety of infections worldwide. Known for their broad-spectrum antimicrobial activity, as well as excellent pharmacokinetics and bioavailability, the use of FQs has risen significantly. While generally well-tolerated, research has indicated that FQs may aggravate collagen-related disorders. These antibiotics increase the activity of matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9, which degrade type I collagen, weakening the structural integrity of tendons. Some studies have demonstrated the association between FQs and the risk of aortic aneurysm or dissection. Given the life-threatening nature of these conditions, these findings are particularly concerning.
- 29 November 2024
- Published by Springer Nature in Cureus
- Vol. 16 (11) , e74740
Open AccessThe Effect of Fluoroquinolones on Aortic Aneurysm and Dissection
Fluoroquinolones (FQs) are a widely prescribed class of antibiotics including ciprofloxacin, levofloxacin, and ofloxacin. They are commonly used to treat a variety of infections worldwide. Known for their broad-spectrum antimicrobial activity, as well as excellent pharmacokinetics and bioavailability, the use of FQs has risen significantly. While generally well-tolerated, research has indicated that FQs may aggravate collagen-related disorders. These antibiotics increase the activity of matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9, which degrade type I collagen, weakening the structural integrity of tendons. Some studies have demonstrated the association between FQs and the risk of aortic aneurysm or dissection. Given the life-threatening nature of these conditions, these findings are particularly concerning.
- Open Access
- 3 September 2024
- Published by Saber UCV in Gaceta Médica de Caracas
- Vol. 132 (3) , 706-718
Actitudes, experiencias y perspectivas en investigación electiva en estudiantes de pregrado de Medicina de la Universidad de Oriente, núcleo Anzoátegui
Introducción: La investigación científica juega un papel fundamental en la práctica médica actual y en el desarrollo académico a nivel mundial. La productividad científica varía considerablemente entre países según su grado de desarrollo. Objetivo: Analizar las actitudes, experiencias y perspectivas en investigación entre los estudiantes de medicina en una universidad autónoma de Venezuela. Materiales y métodos: Se realizó un estudio transversal mediante una encuesta electrónica entre diciembre de 2023 y febrero de 2024, dirigida a estudiantes de medicina de la Universidad de Oriente (UDO), núcleo Anzoátegui.
- 3 September 2024
- Published by Saber UCV in Gaceta Médica de Caracas
- Vol. 132 (3) , 706-718
Open AccessActitudes, experiencias y perspectivas en investigación electiva en estudiantes de pregrado de Medicina de la Universidad de Oriente, núcleo Anzoátegui
Introducción: La investigación científica juega un papel fundamental en la práctica médica actual y en el desarrollo académico a nivel mundial. La productividad científica varía considerablemente entre países según su grado de desarrollo. Objetivo: Analizar las actitudes, experiencias y perspectivas en investigación entre los estudiantes de medicina en una universidad autónoma de Venezuela. Materiales y métodos: Se realizó un estudio transversal mediante una encuesta electrónica entre diciembre de 2023 y febrero de 2024, dirigida a estudiantes de medicina de la Universidad de Oriente (UDO), núcleo Anzoátegui.